Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Breast Cancer

Free Subscription 26.01.2026 4 Ann Surg Oncol 3 BMC Cancer 1 Br J Cancer 2 Breast Cancer 1 Breast Cancer Res 4 Breast Cancer Res Treat 1 Breast J 2 Cancer 1 Cancer Chemother Pharmacol 2 Cancer Lett 1 Cancer Res 9 Clin Breast Cancer 1 Clin Cancer Res 1 Clin Exp Metastasis 1 Eur J Cancer 4 Eur J Surg Oncol 5 J Clin Oncol 2 Mod Pathol 1 N Engl J Med 3 NPJ Breast Cancer 7 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg Oncol

1. BARMETTLER G, Leonard S, Giannakou A, Park KU, et al
   ASO Visual Abstract: Breast Cancer Presentation and Treatment Patterns in Sexual and Gender Minorities.
   Ann Surg Oncol. 2026 Jan 22. doi: 10.1245/s10434-025-19077.
   PubMed        
   
   
2. DAY CN, Habermann EB, Boughey JC
   Evolution of Breast Cancer Treatment 2010-2023.
   Ann Surg Oncol. 2026 Jan 20. doi: 10.1245/s10434-025-19065.
   PubMed         Abstract available
   
   
3. GALLAGHER K, Feldman S, Barone J, Mammen J, et al
   Prospective Phase II Multicenter Trial of Ablation after Breast Lumpectomy Added To Extend (ABLATE) Intraoperative Margins for the Sole Local Treatment of Breast Cancer.
   Ann Surg Oncol. 2026 Jan 18. doi: 10.1245/s10434-025-19008.
   PubMed         Abstract available
   
   
4. SHEN Y, Gadiraju GK, Gao R, Raymakers AM, et al
   ASO Visual Abstract: Breast Reconstruction for Inflammatory Breast Cancer: Improving Patient-Reported Outcomes in a High-Risk Population.
   Ann Surg Oncol. 2026 Jan 17. doi: 10.1245/s10434-025-18841.
   PubMed        
   
   

   
   BMC Cancer

5. AWADA Z, Kazmi N, Jones HJ, Lewis SJ, et al
   The causal association between systolic blood pressure and breast cancer: a two sample Mendelian randomization study.
   BMC Cancer. 2026 Jan 22. doi: 10.1186/s12885-025-15513.
   PubMed        
   
   
6. CAZZANIGA ME, Galimberti S, Pepe FF, Cogliati V, et al
   Metronomic (mCHT) vs standard (sCHT) chemotherapy as first-line treatment in HR+/HER2- Metastatic Breast Cancer (MBC) patients following failure of endocrine treatments. The matched control VICTOR-15 study.
   BMC Cancer. 2026 Jan 20. doi: 10.1186/s12885-025-15482.
   PubMed        
   
   
7. AIKELAIMU A, Li W, Kaicaier M, Liu S, et al
   Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy in breast cancer: a systematic review and meta-analysis with focus on triple-negative subtype and immune-related adverse events.
   BMC Cancer. 2026 Jan 19. doi: 10.1186/s12885-025-15521.
   PubMed        
   
   

   
   Br J Cancer

8. POURALI G, Matthew KA, Jeon MS, Luo C, et al
   Steroid hormone metabolites and mammographic breast density in premenopausal women.
   Br J Cancer. 2026;134:225-236.
   PubMed         Abstract available
   
   

   
   Breast Cancer

9. KAWAMURA C, Iwagami M
   Response to letter to the editor: Risk of endometrial cancer among breast cancer survivors in Japan-a matched cohort study.
   Breast Cancer. 2026 Jan 20. doi: 10.1007/s12282-025-01817.
   PubMed        
   
   
10. YAMAGUCHI-TANAKA M, Takagi K, Takahashi M, Sato A, et al
    Infiltration of TIM4-positive intratumoral macrophages serves as an adverse prognostic factor in breast cancer.
    Breast Cancer. 2026 Jan 21. doi: 10.1007/s12282-026-01825.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

11. LEI L, Bhave M, Kalinsky K, Gandhi S, et al
    Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer.
    Breast Cancer Res. 2026 Jan 22. doi: 10.1186/s13058-025-02203.
    PubMed        
    
    

    
    Breast Cancer Res Treat

12. ALONSO-ROMERO JL, Martinez-Garcia J, Carrillo-Vicente R, Aramburo AF, et al
    Translational and real-world evidence of trastuzumab biosimilar CT-P6 plus pertuzumab in neoadjuvant HER2-positive early breast cancer.
    Breast Cancer Res Treat. 2026;215:60.
    PubMed         Abstract available
    
    
13. STABELLINI N, Kaur J, Owusu C, Moftakhar B, et al
    Real-world outcomes of reduced-dose versus standard-dose antibody drug conjugates in metastatic breast cancer: a retrospective cohort study.
    Breast Cancer Res Treat. 2026;215:59.
    PubMed         Abstract available
    
    
14. PEDERSINI R, Moretti L, Lagana M, Schivardi G, et al
    Fracture risk in metastatic breast cancer patients treated with CDK 4/6 inhibitors and endocrine therapy.
    Breast Cancer Res Treat. 2026;215:58.
    PubMed         Abstract available
    
    
15. WANG Q, Van Alsten SC, Ji X, Salim E, et al
    Molecular and socioeconomic characteristics of inflammatory breast cancer in the Carolina Breast Cancer Study.
    Breast Cancer Res Treat. 2026;215:61.
    PubMed         Abstract available
    
    

    
    Breast J

16. RAO D, Wernecke C, Baron L, Cai S, et al
    Tyrer-Cuzick Lifetime Risk Is Not Associated With Non-BRCA1/2 Pathogenic Variants for Breast Carcinoma.
    Breast J. 2026;2026:8670441.
    PubMed         Abstract available
    
    

    
    Cancer

17. QIU Y, Wu L, Cai W, Chen M, et al
    The evolution and prognostic impact of HER2-low, HER2-ultralow, and HER2-null status in HER2-negative early breast cancer: A pre- to post-neoadjuvant chemotherapy study.
    Cancer. 2026;132:e70269.
    PubMed         Abstract available
    
    
18. ZHAO J, Graetz I, Howard D, Yabroff KR, et al
    Federal and state policies regulating short-term limited-duration insurance plans and timely cancer treatment initiation.
    Cancer. 2026;132:e70190.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

19. OHSHIMA S, Araki T, Yashima H, Ishikawa Y, et al
    Plasma concentrations of doxorubicin and cyclophosphamide during anthracycline-based chemotherapy in a pregnant breast cancer patient: evaluation of gestational changes.
    Cancer Chemother Pharmacol. 2026;96:12.
    PubMed         Abstract available
    
    

    
    Cancer Lett

20. GROZA P, Kumari K, Esteva-Socias M, Schott J, et al
    Fibrillarin-dependent 2'-O-methylation modulates RPS28 ribosome incorporation and oncogenic translation.
    Cancer Lett. 2026;639:218124.
    PubMed         Abstract available
    
    
21. XIA F, Zhu X, Li X, Yi Q, et al
    FIG4 Downregulation-Arrested Autophagy-lysosomal Degradation of IL-18 Drives Lipid-Associated Macrophage Polarization and Immunotherapy Resistance in Triple-Negative Breast Cancer.
    Cancer Lett. 2026 Jan 21:218278. doi: 10.1016/j.canlet.2026.218278.
    PubMed         Abstract available
    
    

    
    Cancer Res

22. CHEN S, Chang C, Liu X, Wang R, et al
    ACSL5 Mediates Adaptation to the Palmitic Acid-Enriched Pulmonary Microenvironment to Enhance Metastatic Breast Cancer Cell Survival and Lung Metastasis.
    Cancer Res. 2026 Jan 22. doi: 10.1158/0008-5472.CAN-25-0866.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

23. OSKA C, Kohilakis E, Feldman S, Tome W, et al
    Intra-Operative Radiotherapy with Photons - Update of a Single Institution Registry Trial.
    Clin Breast Cancer. 2026;26:28-35.
    PubMed         Abstract available
    
    
24. COVINGTON MF, Salmon S, Kozlov A, Archibald Z, et al
    Staging Invasive Lobular Carcinoma: A Prospective Study on the Efficacy of 18F-Fluoroestradiol (FES)-PET/CT.
    Clin Breast Cancer. 2026;26:36-46.
    PubMed         Abstract available
    
    
25. TRAILL M, Jantz J, Richards B, Khalatbari S, et al
    Operating Point Optimization for Efficient Mammogram Triage Using Only Highly Elevated Probability scores.
    Clin Breast Cancer. 2026;26:73-85.
    PubMed         Abstract available
    
    
26. KEANE CA, Iannello MA, Teotia SS, Haddock NT, et al
    Comparing Surgical Management and Reconstruction of Breast Cancer Patients at a Tertiary Care Center and an Associated Safety-Net Institution.
    Clin Breast Cancer. 2025;26:45-49.
    PubMed         Abstract available
    
    
27. BOYANOVA IMB, Aulina LB, Iglesia M, Lopez-Cano D, et al
    Cost Analysis of Technetium-99m versus Indocyanine Green for Sentinel Lymph Node Biopsy in Breast Cancer.
    Clin Breast Cancer. 2025;26:50-58.
    PubMed         Abstract available
    
    
28. ABUALHAJ S, Alshadfan L, Abualhaj MM, Safi Y, et al
    Knowledge, Awareness, Perceptions, and Attitudes Toward Breast Reconstruction Among Breast Cancer Women in Jordan: A Cross-Sectional Study.
    Clin Breast Cancer. 2025;26:59-69.
    PubMed         Abstract available
    
    
29. KLIMITZ FJ, Chiarella LS, Huelsboemer L, Brown S, et al
    Area Deprivation Index (ADI) as a Predictor of Surgical Complications in Patients Undergoing Mastectomy.
    Clin Breast Cancer. 2026;26:150-156.
    PubMed         Abstract available
    
    
30. HETTWER CC, Wurschi GW, Pietschmann K
    A Systematic Review With Individual Patient Data Meta-analysis on Characteristics and Outcomes of Patients With Metaplastic Breast Carcinoma.
    Clin Breast Cancer. 2026;26:139-149.
    PubMed         Abstract available
    
    
31. XIAO XX, Xu PF, Wang MW, Jin S, et al
    Study on Different Staining Platforms for HER2 Cytoplasmic Granular Staining Pattern in Pure Apocrine Carcinoma of the Breast.
    Clin Breast Cancer. 2026;26:221-228.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

32. CONTE B, Braso-Maristany F, Pascual T, Hernando C, et al
    Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like Subtypes.
    Clin Cancer Res. 2026 Jan 22. doi: 10.1158/1078-0432.CCR-25-2570.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

33. RAVICHANDRAN A, Upton K, Taheri S, Liu C, et al
    Digital spatial profiling identifies features of primary and locoregional metastatic vasculature in triple negative breast cancer.
    Clin Exp Metastasis. 2026;43:11.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

34. SPATA A, Ribeiro JM, Vigneri P, Zambelli A, et al
    Comprehensive review of pregnancy associated breast cancer: Clinical features, molecular characteristics and novel therapies.
    Eur J Cancer. 2026;235:116230.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

35. NANDA A, Marshall E, Attia M, Alaradi D, et al
    Targeted axillary dissection after neoadjuvant chemotherapy in breast cancer patients with a high lymph node burden: Radiological and histological outcomes.
    Eur J Surg Oncol. 2026;52:111393.
    PubMed         Abstract available
    
    
36. POTTER S, MacKenzie M, McIntosh S, Gathani T, et al
    Reducing locoregional treatments in low risk early invasive breast cancer.
    Eur J Surg Oncol. 2026;52:111411.
    PubMed         Abstract available
    
    
37. ALVAREZ-LOZADA LA, Salinas-Martinez AM, Pena-Arriaga MD, Valencia-Mercado D, et al
    Meeting expectations and its impact on the quality of life following surgery in breast cancer patients.
    Eur J Surg Oncol. 2026;52:111421.
    PubMed         Abstract available
    
    
38. LEE ES, Calindas-Mendoza MR, Jung SP, Moon HG, et al
    Differential prognostic impact of clinicopathologic factors for late recurrence in ER-positive breast cancer according to menopausal status.
    Eur J Surg Oncol. 2026;52:111419.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

39. BANYS-PALUCHOWSKI M, Hartmann S, de Boniface J, Gentilini OD, et al
    Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study.
    J Clin Oncol. 2026 Jan 21:JCO2501921. doi: 10.1200/JCO-25-01921.
    PubMed         Abstract available
    
    
40. VALENZA C, Nixon NA, Cheung WY, Tolaney SM, et al
    Bridging the Gap: Advancing First-Line Therapy for Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Clin Oncol. 2026 Jan 22:JCO2502942. doi: 10.1200/JCO-25-02942.
    PubMed        
    
    
41. GAO HF, Ye GL, Lin Y, Huang Q, et al
    Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial.
    J Clin Oncol. 2026 Jan 23:JCO2502176. doi: 10.1200/JCO-25-02176.
    PubMed         Abstract available
    
    
42. TARANTINO P
    Rise and Fall of Neoadjuvant Carboplatin for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Clin Oncol. 2026 Jan 23:JCO2502855. doi: 10.1200/JCO-25-02855.
    PubMed        
    
    
43. HILSENBECK SG, Thompson AM
    Windows of Opportunity in Breast Cancer: Learning More From Fewer Patients in a Shorter Time.
    J Clin Oncol. 2026 Jan 23:JCO2502714. doi: 10.1200/JCO-25-02714.
    PubMed        
    
    

    
    Mod Pathol

44. HASHMI AA, Vougiouklakis T, Gazzo A, Wen HY, et al
    Lung Carcinoma Metastatic to the Breast: A Comprehensive Analysis of Clinical Presentation, Morphologic, and Molecular Features, With Emphasis on Diagnostic Pitfalls.
    Mod Pathol. 2026;39:100936.
    PubMed         Abstract available
    
    
45. RAKHA EA, Quinn CM, Provenzano E, Pinder SE, et al
    Diagnostic Discordance and Error in Breast Pathology: Causes, Classifications, and Medicolegal Implications.
    Mod Pathol. 2026;39:100942.
    PubMed         Abstract available
    
    

    
    N Engl J Med

46. TOLANEY SM, de Azambuja E, Kalinsky K, Loi S, et al
    Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2026;394:354-366.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

47. SHI W, Luo Y, Wang Y, Burrows JM, et al
    CRISPR screens identify PRMT7 as a therapeutic target to enhance T cell-mediated killing in breast cancer.
    NPJ Breast Cancer. 2026 Jan 21. doi: 10.1038/s41523-025-00888.
    PubMed         Abstract available
    
    
48. FARROKHI P, Park L, Schmutz W, Thompson SL, et al
    Racial differences in biomarkers, treatment, and outcomes in HR+/HER2- metastatic breast cancer in the United States.
    NPJ Breast Cancer. 2026 Jan 23. doi: 10.1038/s41523-026-00891.
    PubMed         Abstract available
    
    
49. NAGASAWA S, Kajiya K, Ishikawa E, Kanai A, et al
    Spatial gene expression analysis reveals drivers of extremely early lymph node metastasis in breast cancer.
    NPJ Breast Cancer. 2026 Jan 23. doi: 10.1038/s41523-026-00897.
    PubMed         Abstract available
    
    

    
    PLoS One

50. POELHEKKEN K, Greuter MJW, Dorrius MD, de Bock GH, et al
    Influence of follow-up, screening age, interval, and compliance on overdiagnosis of ductal carcinoma in situ (DCIS): A modelling study.
    PLoS One. 2026;21:e0331821.
    PubMed         Abstract available
    
    
51. FILIPOV T, Teutsch B, Vass D, Budinszki B, et al
    Cryoablation for fibroadenoma with liquid nitrogen based system: A retrospective analysis of prospectively collected data.
    PLoS One. 2026;21:e0340969.
    PubMed         Abstract available
    
    
52. 
    Retraction: Regulating BMI1 expression via miRNAs promote Mesenchymal to Epithelial Transition (MET) and sensitizes breast cancer cell to chemotherapeutic drug.
    PLoS One. 2026;21:e0341297.
    PubMed        
    
    
53. CHAVDA T, Lawal A, Sowunmi A, Adegboyega B, et al
    Validation and limitations of the distress thermometer in identifying depression among metastatic breast cancer patients in Nigeria: Methodological challenges in depression-specific screening validation.
    PLoS One. 2026;21:e0341221.
    PubMed         Abstract available
    
    
54. YE L, Yu G, Cheng Y, Fan L, et al
    DnaK supports intracellular persistence of Staphylococcus xylosus and confers mechanical resilience to a human breast cancer cell line.
    PLoS One. 2026;21:e0341069.
    PubMed         Abstract available
    
    
55. YING K, Xue H, Du S, Wang X, et al
    Zwitterionic molecularly imprinted polymers for selective capillary microextraction of N1,N12-Diacetylspermine (DiAcSpm) from breast cancer.
    PLoS One. 2026;21:e0339776.
    PubMed         Abstract available
    
    
56. KUMAR ARK, Shaji CS, Rajagopalan A, Bhattacharya S, et al
    Increased sensitivity of etoposide-treated breast cancer cells with an ATM inhibitor.
    PLoS One. 2026;21:e0340472.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.